Congress funds women's health research push, seats pharma at the table

What it does

This bill directs the Department of Health and Human Services to run two public awareness campaigns—one to increase women's participation in NIH clinical trials generally, and another focused on bleeding and clotting disorders—and establishes a permanent interagency task force to coordinate federal efforts on rare disease research and treatment, with particular attention to conditions affecting women. The bill authorizes $10 million per year for five years for each campaign and requires HHS to produce an action plan within 180 days on coordinating rare-disease research that disproportionately affects women.

Why we flagged it

The bill's core function is establishing federal coordination mechanisms and public awareness campaigns for women's health and rare disease research—a public health infrastructure measure, not a commemorative or vanity bill despite its eponymous title.

What the text implies

• The task force includes four appointed positions for 'biopharmaceutical innovators' with respect to rare diseases, creating a formal channel for private pharmaceutical industry input into federal research prioritization and incentive design—potentially shaping which rare diseases receive public research support.
• The bill's focus on 'rare diseases and conditions that disproportionately impact women' may create a research-funding bias toward conditions affecting women, potentially reducing relative attention to rare diseases affecting other populations, though this reflects a deliberate policy choice rather than a hidden mechanism.
• The action plan requirement (Section 5) mandates public posting of HHS's rare-disease research strategy, creating transparency but also potentially signaling to private firms which therapeutic areas the federal government intends to incentivize, allowing market actors to align R&D accordingly.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands public health research infrastructure and awareness in areas historically underserved—women's health and rare diseases—without creating new restrictions on citizens or private liability shields. It increases federal transparency and coordination on research priorities that affect public health outcomes.

Who stands to gain

• biopharmaceutical companies developing rare disease treatments
• clinical research institutions and hospitals conducting NIH-funded trials
• private health plan administrators (task force members)

Named in the bill

Department of Health and Human Services (HHS), National Institutes of Health (NIH), Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), rare disease advocacy groups, biopharmaceutical companies

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Feb 25, 2026 — Introduced · Congress.gov: “Introduced in House”
• Feb 25, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $156,000 in lobbying spend. A filing names 55 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Josh Gottheimer, the sponsor, reported $1,000,800 in PAC receipts in the 2026 cycle.

• American College of Obstetricians and Gynecologists — $96,000 on 1 filing
• Hadassah, the Women's Zionist Organization of America, Inc. — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.